An observational study assessing long term safety of Tenofovir-disoproxil-fumarate on bone mineral density in HIV infected youths

Trial Profile

An observational study assessing long term safety of Tenofovir-disoproxil-fumarate on bone mineral density in HIV infected youths

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Efavirenz
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Apr 2016 New trial record
    • 25 Feb 2016 Results presented at the 23rd Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top